• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5635
    • Acute Myelogenous Leukemia 148
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 120
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 147
    • Chronic Myelogenous Leukemia 16
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 243
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 83
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 332
    • Myeloproliferative Disease 15
    • News 110
    • Non-Hodgkin Lymphoma 43
    • Non-Small Cell Lung Cancer 267
    • Other 110
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    Promising results for axitinib and pembrolizumab in advanced renal cell cancer
    00:03:29

    Promising results for axitinib and pembrolizumab in advanced renal cell cancer

    Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination with pembrolizumab for the first-line treatment of advanced renal cell cancer (NCT02133742). Dr Atkins goes onto explain the next steps required for this result to impact treatment, and eagerly awaits the results of the KEYNOTE-426 trial (NCT02853331). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

    101 Views
    1 year ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Live

    Trending

    Next Gen Immune Activation In Kidney Cancer
    00:00:44

    Next Gen Immune Activation In Kidney Cancer

    42 Views
    10 months ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Tumor Enucleation Debate
    00:00:54

    Tumor Enucleation Debate

    112 Views
    10 months ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Should We Be Doing Robotic Radical Nephrectomy
    00:01:14

    Should We Be Doing Robotic Radical Nephrectomy

    68 Views
    11 months ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    What is the best front line treatment for metastatic ?clear cell RCC in 2018?
    00:27:47

    What is the best front line treatment for metastatic ?clear cell RCC in 2018?

    95 Views
    1 year ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation
    00:08:52

    Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation

    60 Views
    1 year ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Checkmate-214 has a Higher Response Rate | 9% of Patients Went on to Complete Response
    00:01:04

    Checkmate-214 has a Higher Response Rate | 9% of Patients Went on to Complete Response

    109 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
    0:11:28

    DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells

    11 Views
    3 weeks ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
    0:08:15

    Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma

    30 Views
    3 weeks ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Kidney Cancer Experts at UT Southwestern discuss the CARMENA trial
    00:19:50

    Kidney Cancer Experts at UT Southwestern discuss the CARMENA trial

    238 Views
    1 year ago
    admin
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Optimizing treatment for renal cell carcinoma with sequential therapies
    00:01:09

    Optimizing treatment for renal cell carcinoma with sequential therapies

    72 Views
    1 year ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Predictive Biomarkers In Selecting Patient Populations For I-O Treatment In RCC
    00:01:44

    Predictive Biomarkers In Selecting Patient Populations For I-O Treatment In RCC

    49 Views
    8 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE A brief overview 2014-2019 Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE A brief overview 2014-2019
    0:14:22

    Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE A brief overview 2014-2019

    2 Views
    3 weeks ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Latest Videos

    Treatment-Free Survival, With and Without Toxicity Treatment-Free Survival, With and Without Toxicity
    0:05:48

    Treatment-Free Survival, With and Without Toxicity

    10 Views
    2 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1 Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
    0:02:51

    Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1

    1 Views
    2 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    What's To Come in Modern Imaging Technology What's To Come in Modern Imaging Technology
    0:03:54

    What's To Come in Modern Imaging Technology

    4 Views
    3 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Modern Imaging Technology Modern Imaging Technology
    0:02:04

    Modern Imaging Technology

    10 Views
    4 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Management of Clinical Cases in Kidney Cancer Management of Clinical Cases in Kidney Cancer
    0:01:59

    Management of Clinical Cases in Kidney Cancer

    11 Views
    5 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Kidney Cancer Program & SPORE Kidney Cancer Program & SPORE
    0:09:10

    Kidney Cancer Program & SPORE

    9 Views
    5 days ago
    kidneycancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Copyright 2019 Medicus Networks, Inc.